Please provide your email address to receive an email when new articles are posted on . Postdischarge pharmacotherapy rates rose from 12.6% in 2014 to 23.9% in 2023 for ALD-related hospitalizations.
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence ...
SEATTLE and VANCOUVER, British Columbia, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the development and ...
Achieve Life Sciences Inc. (NASDAQ:ACHV) is moving closer to a pivotal moment as it seeks FDA approval for cytisinicline, a potential first new smoking cessation therapy in nearly two decades, ...
Bethesda, MD -Persuading patients with left ventricular dysfunction (LVD) to eschew tobacco will benefit them just as much as treating them with medication, a Canadian study led by Dr Neville Suskin ...
Despite decades of progress in reducing the prevalence of cigarette smoking, tobacco use remains a leading cause of preventable death and disease, and a significant driver of health care costs in the ...
Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully ConcludedDSMC Completes Final Review of Cytisinicline, Finds ...
A large cohort study found no increased risk for major congenital malformations (MCMs) among infants with prenatal exposure to nicotine replacement therapy (NRT), varenicline, or bupropion within 90 ...
Lorain County Public Health is urging residents to take a step toward improving their health by quitting all forms of tobacco ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback